{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:27:13Z","timestamp":1784352433149,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04876-8","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:02:03Z","timestamp":1710604923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial \u201cGIVE ME FIVE\u201d"],"prefix":"10.1007","volume":"42","author":[{"given":"Giulia","family":"Marvaso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Repetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lorubbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Bellerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-4634","authenticated-orcid":false,"given":"Mattia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Vincini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Zerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luzzago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Alessandro","family":"Mistretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Cambria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Petralia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"4876_CR1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047\u20131060","journal-title":"Lancet Oncol"},{"key":"4876_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209\u2013249","journal-title":"CA A Cancer J Clin"},{"key":"4876_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(14)70361-4","volume":"15","author":"JA Lane","year":"2014","unstructured":"Lane JA et al (2014) Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 15:1109\u20131118","journal-title":"Lancet Oncol"},{"key":"4876_CR4","unstructured":"Schaeffer E, An Y, Barocas, D, et al (2022) NCCN Guidelines Version 1.2023 Prostate Cancer. 2022. https:\/\/www.nccn.org\/home\/. Accessed 16 Oct 2023"},{"key":"4876_CR5","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 14 (09\u201322) Gy. Int J Radiat Oncol Biol Phys 82:e17-24","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijrobp.2019.07.027","volume":"105","author":"G Marvaso","year":"2019","unstructured":"Marvaso G et al (2019) Comparison of outcomes and toxicity between extreme and moderate radiation therapy hypofractionation in localized prostate cancer: a propensity score analysis. Int J Radiat Oncol Biol Phys 105:735\u2013744","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","volume":"29","author":"TP Boike","year":"2011","unstructured":"Boike TP et al (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020\u20132026","journal-title":"J Clin Oncol"},{"key":"4876_CR8","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.1016\/j.ijrobp.2012.04.012","volume":"84","author":"V Fonteyne","year":"2012","unstructured":"Fonteyne V et al (2012) Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys 84:e483-490","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King CR, Brooks JD, Gill H, Presti JC (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877\u2013882","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","volume":"59","author":"R Hannan","year":"2016","unstructured":"Hannan R et al (2016) Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer 59:142\u2013151","journal-title":"Eur J Cancer"},{"key":"4876_CR11","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34:2325\u20132332","journal-title":"J Clin Oncol"},{"key":"4876_CR12","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35:1884\u20131890","journal-title":"J Clin Oncol"},{"key":"4876_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson WC et al (2019) Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 104:778\u2013789","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR14","doi-asserted-by":"publisher","first-page":"20160725","DOI":"10.1259\/bjr.20160725","volume":"91","author":"G Timon","year":"2018","unstructured":"Timon G et al (2018) Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. Br J Radiol 91:20160725","journal-title":"Br J Radiol"},{"key":"4876_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2016.08.005","volume":"50","author":"B De Bari","year":"2016","unstructured":"De Bari B et al (2016) Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev 50:48\u201360","journal-title":"Cancer Treat Rev"},{"key":"4876_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.vhri.2016.08.001","volume":"10","author":"M Tambas","year":"2016","unstructured":"Tambas M et al (2016) Conventionally fractionationed volumetric arc therapy versus hypofractionated stereotactic body radiotherapy: quality of life, side effects, and prostate-specific antigen kinetics in localized prostate cancer. Value Health Reg Issues 10:91\u201399","journal-title":"Value Health Reg Issues"},{"key":"4876_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","volume":"102","author":"HR Lukka","year":"2018","unstructured":"Lukka HR et al (2018) Patient reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. Int J Radiat Oncol Biol Phys 102:287\u2013295","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","volume":"22","author":"P Fransson","year":"2021","unstructured":"Fransson P et al (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22:235\u2013245","journal-title":"Lancet Oncol"},{"key":"4876_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC et al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23:1308\u20131320","journal-title":"Lancet Oncol"},{"key":"4876_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.prnil.2018.03.005","volume":"6","author":"T Feutren","year":"2018","unstructured":"Feutren T, Herrera FG (2018) Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. Prostate Int 6:75\u201387","journal-title":"Prostate Int"},{"key":"4876_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans C et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol 147:92\u201398","journal-title":"Radiother Oncol"},{"key":"4876_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","volume":"53","author":"N Cellini","year":"2002","unstructured":"Cellini N et al (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53:595\u2013599","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijrobp.2007.03.065","volume":"69","author":"D Pucar","year":"2007","unstructured":"Pucar D et al (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69:62\u201369","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","volume":"13","author":"HU Ahmed","year":"2012","unstructured":"Ahmed HU et al (2012) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 13:622\u2013632","journal-title":"Lancet Oncol"},{"key":"4876_CR25","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","volume":"82","author":"E Arrayeh","year":"2012","unstructured":"Arrayeh E et al (2012) Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 82:e787-793","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02873","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"key":"4876_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio M et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910\u2013915","journal-title":"J Clin Oncol"},{"key":"4876_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12032-020-01397-3","volume":"37","author":"G Marvaso","year":"2020","unstructured":"Marvaso G et al (2020) Phase II prospective trial \u2018Give Me Five\u2019 short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). Med Oncol 37:74","journal-title":"Med Oncol"},{"key":"4876_CR29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.5301\/tj.5000547","volume":"102","author":"G Timon","year":"2016","unstructured":"Timon G et al (2016) Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion. Tumori 102:536\u2013540","journal-title":"Tumori"},{"key":"4876_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach","year":"2006","unstructured":"Roach M et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965\u2013974","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR31","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341\u20131346","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4876_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385\u2013395","journal-title":"Lancet"},{"key":"4876_CR33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.clon.2016.02.005","volume":"28","author":"NG Di Muzio","year":"2016","unstructured":"Di Muzio NG et al (2016) Moderate hypofractionation with simultaneous integrated boost in prostate cancer: long-term results of a phase I-II study. Clin Oncol (R Coll Radiol) 28:490\u2013500","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"4876_CR34","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/cncr.11233","volume":"97","author":"RM Hoffman","year":"2003","unstructured":"Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL (2003) Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 97:1653\u20131662","journal-title":"Cancer"},{"key":"4876_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5534\/wjmh.2012.30.2.99","volume":"30","author":"JS Hyun","year":"2012","unstructured":"Hyun JS (2012) Prostate cancer and sexual function. World J Mens Health 30:99\u2013107","journal-title":"World J Mens Health"},{"key":"4876_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/jnci\/djx218","volume":"110","author":"JR Broughman","year":"2018","unstructured":"Broughman JR et al (2018) Prostate cancer patient characteristics associated with a strong preference to preserve sexual function and receipt of active surveillance. J Natl Cancer Inst 110:420\u2013425","journal-title":"J Natl Cancer Inst"},{"key":"4876_CR37","unstructured":"ASCO GU (2023) PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)\u2014Primary Endpoint Analysis. https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2023\/asco-gu-2023-prostate-cancer\/142476-asco-gu-2023-pace-a-an-international-phase-3-randomised-controlled-trial-rct-comparing-stereotactic-body-radiotherapy-sbrt-to-surgery-for-localised-prostate-cancer-lpca-primary-endpoint-analysis.html. Accessed 16 Oct 2023"},{"key":"4876_CR38","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375:1425\u20131437","journal-title":"N Engl J Med"},{"key":"4876_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fonc.2014.00301","volume":"4","author":"AJ Katz","year":"2014","unstructured":"Katz AJ, Kang J (2014) Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol 4:301","journal-title":"Front Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04876-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04876-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04876-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:23:55Z","timestamp":1735853035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04876-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4876"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04876-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the present study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. This trial had been approved by the Ethics Committee of the IEO and Centro Cardiologico Monzino of Milan IEOS768\/113. All patients signed a dedicated Informed Consent before admission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"169"}}